Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE (0.23%), DAX (0.03%), CAC (0.01%)

Sep 25 ,2025

  • Synopsis

    • European equity markets are set to open in negative territory amid Asian equities mostly higher Thursday. Greater China markets nudging higher with autos a standout in Hong Kong. Japan flat. Benchmarks in Australia, Korea and Taiwan little changed. S&P 500 futures up slightly afterhours. Bonds mixed with Treasuries and JGBs little changed while Australian yields backing up following hawkish takeaways from Wednesday's CPI print. Dollar weakest against Aussie, yen and Koran won, steady elsewhere. Crude coming off highs that followed hawkish Trump shift on Russia. Gold flat after pulling back from record high. Bitcoin extending retreat from overnight high.

    • In central banks, SNB interest rate decision at 9:30CET - benchmark unchanged at 0.0%, with news conf. ECB's latest Economic Bulletin published at 10:00CET. Slovak central bank publishes its Autumn Economic and Monetary Development. Chancellor Merz participates in the Conf. of Minister-Presidents of the Eastern European Regions, joint press conf planned at conclusion. Also on Thur, European Automobile Manufacturers' Association (ACEA) Aug new passenger car registrations for EU + EFTA + UK and UK Aug car production is out for release.

    • Macroeconomic updates include: Germany Oct consumer confidence - GfK, France Sep consumer confidence, Eurozone Aug M3 money supply, Norway Aug unemployment rate, Sweden Aug PPI, UK Sep distributive trades - CBI

    • In corporate news, Trigano (TRI.FP) reported preliminary FY revenue yesterday after the EU close. MFE-MEDIAFOREUROPE (MFEB.IM) also released H1 earnings yesterday evening whilst Biofrontera AG (B8FK.GR) announced expected impairment losses. This morning, KWS SAAT SE & Co. KGaA (KWS.GR) released FY earnings, adopted new dividend policy and provided guidance for FY25/26 as well as medium-term targets for 2028. TKH Group (TWEKA.NA) presents 'Capitalize & Execute 2028' strategy during CMD today. OCI (OCI.NA), Fluxys Belgium (FLUX.BB), H&M Hennes & Mauritz (HM.B.SS), are among other companies in the region expected to update investors with their latest earnings.

  • Politics/Macro/World News

    • European officials fear Trump is preparing to blame them for Ukraine failure - FT

    • UK energy chief eyes an oil and gas loophole - Politico

    • Spain's Sanchez says he plans to run for re-election in 2027 - Bloomberg

    • US tariff cut boosts EU auto sector amid industry challenges - Bloomberg

  • Top company news

    • Earnings/updates

      • QDT.FP (Quadient) -- reports H1 net income from cont ops €21M vs year-ago €26M

      • TRI.FP (Trigano) -- reports preliminary FY revenue €3.66B vs FactSet €3.71B [9 est, €3.67-3.79B]

      • MFEB.IM (MFE-MEDIAFOREUROPE) -- reports H1 net income €130.2M, +24% vs year-ago €104.7M

      • B8FK.GR (Biofrontera AG) -- announces expected impairment losses

      • GBT.FP (Guerbet) -- reports final H1 earnings: net income €1.3M vs year-ago €10.0M

      • BEN.FP (Beneteau) -- reports H1 net income (€24.8M) vs year-ago €49.4M

      • SEQUA.BB (Sequana Medical) -- reports H1 net income (€18.3M) vs year-ago (€11.1M); forecasts completion of at least 70 commercial implants in the US before end of Q1 2026

      • TWEKA.NA (TKH Group) -- presents 'Capitalize & Execute 2028' strategy during CMD today

      • KWS.GR (KWS SAAT SE & Co. KGaA) -- reports FY EPS €4.24 vs FactSet €5.08 [5 est, €4.49-5.57]

    • M&A

      • SSPG.LN (SSP Group) -- Activist Irenic Capital seeking to elicit takeover interest in SSP Group after boosting stake - FT

      • AEDAS.SM (AEDAS Homes) -- Neinor Homes to propose to shareholder meeting the acquisition of Aedas Homes through a voluntary tender offer

      • SOP.FP (Sopra Steria Group) -- in talks for potential acquisition of Neocase

      • FAGR.BB (Fagron) -- agrees to acquire University Compounding Pharmacy for ~$41.5M (enterprise value); provides FDA inspection update

      • BLC.FP (Bastide Le Confort Medical) -- completes sale of Baywater Healthcare to Sapio Group

      • ES.FP (Esso) -- North Atlantic signs agreement to acquire ExxonMobil France Holding's stake in Esso and ExxonMobil Chemical France

      • VRAP.FP (Vranken-Pommery Monopole) -- announces negotiations regarding sale of Heidsieck & Co Monopole

      • ENI.IM (Eni) -- completes sale of 30% stake in the Baleine project in Côte d'Ivoire to Vitol; price not disclosed

    • Healthcare

      • GSK.LN (GSK Plc) -- Transcript Intelligence: GSK Plc at Bank of America Global Healthcare Conference

      • SDZ.SW (Sandoz Group) -- announces US launch of its generic iron sucrose injection

      • HNSA.SS (Hansa Biopharma) -- AB announces Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

      • SANN.SW (Santhera Pharmaceuticals Holding) -- Santhera provides update on Convertible Bond Issued on 23-Sep-25

    • Other

      • IFX.GR (Infineon Technologies) -- Infineon sees huge growth opportunities for semiconductor industry amid combination of AI with advanced sensors and actuators - Nikkei

      • BAS.GR (BASF SE) -- Freeport site in TX to be powered by 100% renewable energy

      • TTE.FP (TotalEnergies) -- to adjust the pace of share buybacks

      • FR.FP (Valeo SE) -- announces contract with Chinese automaker

      • GTT.FP (Gaztransport & Technigaz) -- receives order from Samsung Heavy Industries for the design of tanks for two new LNG carriers

      • NDA.GR (Aurubis) -- announces first US multimetal recycling plant starts production of strategic metals

      • YCA.LN (Yellow Cake) -- places upsized 23.0M new shares at 564p/share through Canaccord Genuity

      • BSLN.SW (Basilea) -- awarded BARDA contract for tdevelopment of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam; total non-dilutive funding of up to $159M

  • Key rating changes

    • Downgrades

      • HEXA.B.SS (Hexagon) -- to hold from buy at Pareto

    • Initiations

      • OMV.AV (OMV) -- sector perform at RBC Capital Markets

  • Data

    • Nikkei +0.20% to 45721.07

    • Hang Seng (0.21%) to 26462.43

    • Shanghai Composite (0.32%) to 3841.27

    • S&P futures +4.5 vs prior close of 6692.3

    • €-$ +0.0003 or +0.03% to 1.1742

    • $-¥ (0.10) or (0.07%) to 148.80

    • €-¥ (0.07) or (0.04%) to 174.72

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE